HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...
Nasdaq3d
HOOKIPA Pharma Completes Enrollment in Phase 1b Clinical Trial of HB-500 for HIV Treatment in Collaboration with Gilead Sciences, Inc.
HOOKIPA Pharma Inc. has announced the completion of participant enrollment in a Phase 1b clinical trial for HB-500, a next-generation therapeutic vaccine aimed at treating HIV. The trial ...
US health agencies scrub HIV, other data to remove 'gender ideology'
The U.S. Centers for Disease Control and Prevention and other federal health agencies on Friday took down webpages with ...
Yahoo Finance3d
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
The Phase 1b clinical trial (NCT06430905) is evaluating the safety and tolerability, reactogenicity, and immunogenicity to repeated doses of HB-500 in participants with HIV on suppressive ...
US restores crucial HIV treatment access for millions as South African organisations voice funding fears
The decision, made by US Secretary of State Marco Rubio, enables individuals in 55 countries, including South Africa, to ...
A cure for HIV: 'One of the hardest goals in science'
Curing HIV will be harder than curing cancer. Apart from a few 'miracle' cases, antiretrovirals only suppress HIV, they don't ...
Daily7h
European Commission authorises ViiV Healthcare Vocabria plus Rekambys for HIV treatment in adolescents
London: GSK plc has announced that ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced that the European Commission has ...